Clinical trial news
Discussion
Taldefgrobep alfa did not significantly improve motor function across the total population of treated spinal muscular atrophy (SMA) patients in a pivotal Phase 3 clinical trial, but significant improvements were seen among Caucasian participants. That’s according to trial results announced by the therapy’s developer, Biohaven Pharmaceuticals. The…
Branaplam (also known as LMI070) is an oral small molecule that was being developed as a potential therapy for SMA. In 2021 its development was discontinued based on the fact that the therapy would no longer represent a highly differentiated option for SMA patients.
Discussion
An experimental high-dose regimen of spinal muscular atrophy (SMA) treatment Spinraza (nusinersen) is showing motor benefits for previously untreated patients of all ages, as well as those who switched over from Spinraza’s approved dose, according to new data from the DEVOTE clinical trial. Among babies who’d never received…
Discussion
Scholar Rock’s apitegromab led to motor function improvements over a year of treatment in young adults and children with spinal muscular atrophy (SMA) type 2 or 3 who could sit independently and were on stable standard of care, but unable to walk. That’s according to…
